ADRB1 and Arrhythmia: Taken together, these results demonstrate the therapeutic capability of C11 in mitigating exercise-induced arrhythmias associated with the pathological overactivation of β1ARs in the heart and underscore its potential as a new class of drug to block the β1AR in disease states.